Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020

Zacharoula Bogogiannidou1, Alexandros Vontas1, Katerina Dadouli1, Maria A Kyritsi1, Soteris Soteriades1, Dimitrios J Nikoulis1, Varvara A Mouchtouri1, Michalis Koureas2, Evangelos I Kazakos3, Emmanouil G Spanos4, Georgia Gioula4, Evangelia E Ntzani5-6, Alexandros A Eleftheriou7, Alkiviadis Vatopoulos8, Ethimia Petinaki9, Vassiliki Papaevangelou9, Matthais Speletas10, Sotiros Tsirodas10, Christos Hadjichristodoulou1

1. Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, Larissa, Greece
2. Faculty of Midwifery, School of Health Sciences, University of Western Macedonia, Kozani, Greece
3. National Influenza Reference Laboratory for Northern Greece, Microbiology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
4. Department of Hygiene and Epidemiology, University of Ioannina Faculty of Medicine, Ioannina, Greece
5. Center for Evidence Synthesis in Health, Department of Health Services, Policy and Practice, School of Public Health, Brown University, Providence, United States
6. Institute of Biosciences, University Research Center of Ioannina, Ioannina, Greece
7. Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece
8. Department of Microbiology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
9. Third Department of Paediatrics, National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece
10. Department of Immunology and Histocompatibility, Faculty of Medicine, University of Thessaly, Larissa, Greece
11. Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece

Correspondence: Christos Hadjichristodoulou (xhatzi@uth.gr)

A serosurvey of IgG antibodies against severe acute respiratory coronavirus 2 (SARS-CoV-2) was performed during March and April 2020. Among 6,586 leftover sera, 24 (0.36%) were positive, with higher prevalence in females, older individuals and residents of large urban areas. Seroprevalence was estimated at 0.02% and 0.25%, respectively, in March and April, infection fatality rate at 2.66% and 0.54%. Our findings confirm low COVID-19 incidence in Greece and possibly the effectiveness of early measures.

On 10 March 2020, with 89 active coronavirus disease (COVID-19) cases and 0 deaths reported, the Greek government decided to suspend the operation of all educational institutions throughout the country [1]. Gradually, restrictive measures were extended and resulted in a general lockdown on 23 March [2], when 649 active cases and two deaths had been recorded. By 30 April 2020, Greece had reported 2,310 laboratory confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the general population and 140 related deaths [3]. The recorded cumulative incidence of COVID-19 in Greece until 30 April was estimated at 24.3 cases per 100,000 population and the mortality at 1.3 deaths per 100,000 population, which are considered low in comparison with other countries worldwide [4].

The aims of the present sero-epidemiological study were to estimate the prevalence of severe acute respiratory coronavirus 2 (SARS-CoV-2) IgG antibodies in the population of Greece by sex, age group and geographical area, to provide evidence for the potential under-diagnosis of COVID-19 in Greece, to identify regional differences in order to improve surveillance and finally, to assess the infection fatality rate (IFR) and compare it to the case fatality rate (CFR).

Study design and participants

Blood samples were collected by using the leftover sampling methodology (residual sera from the general population) [5]. We applied a geographically stratified sampling plan based on regional units (NUTS level 3) to produce a representative sample, taking into consideration age group (0–29, 30–49, 50–69, ≥ 70 years) and sex. The required sample size was determined to be 380 blood samples from each of the 13 NUTS level 2 regions, and the sample size for each regional unit (NUTS level 3) from the corresponding region was calculated according to population distribution. However, the number of actual samples collected differed from the pre-determined number of samples above. The study was designed as a cross-sectional survey and repeated at monthly intervals. Here we present the results from March and April 2020. The leftover blood samples were collected from a nationwide laboratory
network, including both private and public hospital laboratories (27 laboratories in total). The samples were collected from individuals who visited the laboratories for a check-up, chronic disease follow-up or other reasons unrelated to COVID-19. The geographical distribution of the collected leftover samples is shown in the Figure. We collected 1,575 samples from Central Macedonia, 1,133 from Attica, 1,115 from Peloponnese, 853 from Thessaly, 759 from Western Macedonia, 494 from Central Greece, 371 from Western Greece and 286 from Epirus. Age, sex, residence and the date of blood sampling were recorded.

Laboratory analysis
The presence of IgG antibodies against SARS-CoV-2 was determined using the ABBOTT SARS-CoV-2 IgG assay, a chemiluminescent microparticle immunoassay (CMIA), with the ARCHITECT i2000SR analyzer (Abbott, Illinois, United States). The method was validated in our laboratory using 305 pre-COVID-19 samples (obtained in 2017) as negative controls and 94 samples from patients with positive SARS-CoV-2 PCR and different symptom durations. The kit displayed 84.0% sensitivity (95% confidence interval (CI): 76.6–91.5) and 99.7% specificity (95% CI: 98.2–100). All positive samples, as well as 100 randomly chosen samples negative in the ABBOTT assay were confirmed with ELISA kits such as the Vircell COVID-19 IgG (Vircell Spain S.L.U., Granada, Spain) and the Euroimmun SARS-CoV-2 IgG (Euroimmun, Lübeck, Germany).

Statistical analysis
Weighted prevalence
Initially, we determined an unweighted relative frequency of all patient characteristics (age, sex and area of residence): this is the crude seroprevalence (S1). The weighted proportions of positive tests in the countrywide sample were based on the sex and age distribution within each regional unit (NUTS level 3) and the
population of each regional unit, according to the 2011 census (S2) [6]. We also adjusted the weighted proportion (S2) of positive tests to account for the accuracy (sensitivity and specificity) of the laboratory test (S3) [7-9]. Since the reported COVID-19 cases were by definition outside the sampling framework, the sero-prevalence was calculated, taking into consideration the number of reported cases per month in accordance with the National Public Health Organisation (NPHO) (S4). Therefore, we added the cases reported in March to the estimated S3 seroprevalence in order to calculate the S4 for March, while to calculate the S4 for April, we added the reported cases from March and April. We calculated the S1, S2, S3 and S4 seroprevalence of IgG antibodies by month, the CFR and the IFR. CFR is the ratio of the number of deaths attributed to COVID-19 and the number of cases reported to the NPHO. IFR is the ratio of deaths divided by the number of estimated people infected with SARS-CoV-2. The estimation of infected people was the product of the seroprevalence and the population of regional units where confirmed cases were found according to NPHO [3,10,11]. The 95% CI for weighted data were estimated using normal approximation of binomial distribution and effective sample size instead of the collected sample size, further explained below. It should be noted that clusters of cases from refugee camps and from a cruise ferry that were not considered community cases (302 cases in total) were excluded from the analysis for CFR and IFR. The 95% CI for CFR were calculated using normal approximation of binomial distribution. The 95% CI for IFR were calculated using the corresponding 95% CI of the S1, S2, S3 and S4 seroprevalence. Comparison of two proportions was done with the ‘N-1’ chi-squared test [10]. For all analyses, a 5% significance level was set.

Effective sample size
Since the number of collected samples from each regional unit was not proportional to the regional unit’s population, we calculated an effective sample size based on each regional unit’s population proportion, according to 2011 census data. This was done using target weighting. The target sample size for a regional unit i is \( t_i \), and the actual sample size for the regional unit i is \( a_i \). The weighting factor for the regional unit i is calculated with the following formula:

\[
f_i = \frac{t_i}{a_i} \quad \text{(Formula 1)}
\]

The weighted sample size \( w_i \) for the regional unit i is calculated as follows:

\[
w_i = t_i \times f_i \quad \text{(Formula 2)}
\]

For \( k \) regional units and a countrywide target sample size of \( n_t \), the country-wide effective sample size \( (n_e) \) is calculated with the following formula:

\[
n_e = \frac{n_t^2}{\sum_{i=1}^{k} w_i^2} \quad \text{(Formula 3)}
\]

This can also be written as:

\[
n_e = \frac{\left(\sum_{i=1}^{k} t_i^2 \right)^2}{\sum_{i=1}^{k} \frac{t_i^2}{w_i}} \quad \text{(Formula 4)}
\]

Ethical statement
The data were anonymised and the laboratories requested a written consent statement from the participants. The study was approved by the ethical committee of the Faculty of Medicine, University of Thessaly (No. 2116).

Serosurvey results
Twenty-four of 6,586 (0.36%) collected samples were found positive for anti-SARS-CoV-2 IgG antibodies. Regarding samples from March, five of 2,075 (S1 = 0.24%) were positive (Table 1), while 19 of 4,511 (S1 = 0.42%) samples from April were IgG positive (Table 2). As shown in Tables 1 and 2, the S2 and S3 seroprevalences were higher in April than in March: S2 = 0.27% and S3 = 0% in March vs S2 = 0.49% and S3 = 0.23% in April vs S2 = 0.27% and S3 = 0% in March. The S2 and S3 among females were higher than among males for both months, with the higher percentage occurring in April (females: S2 = 0.94%, S3 = 0.76% vs males: S2 = 0.46%, S3 = 0.19%). Moreover, in large urban areas (Attica region and Thessaloniki regional unit) in April, the S2 (0.99%) and S3 (0.83%) were higher than the estimated S2 (0.27%) and S3 (0%) in the rest of the country. A gradual increase of S4 by age was prominent in April, from 0.02% in the age group 0–29 years to 1.17% in the age group ≥ 70 years.

By using the total reported cases (2,310) until 30 April 2020 and the S3 seroprevalence, we estimated that every case confirmed by RT-PCR corresponded to 10.2 (95% CI: 0–21.2) COVID-19 cases in the Greek population.

Finally, according to NPHO data and our results, the CFR in March was calculated as 3.61% and the IFR as 2.66%; for April the corresponding values were 6.06% and 0.54% for CFR and IFR, respectively (Tables 1 and 2).

Discussion
The reported incidence and mortality of COVID-19 during March and April 2020 in Greece were among the lowest in Europe. During the same period, 75,170 RT-PCR tests (which corresponds to a rolling 7-day average of 0.22 per 1,000 population for 23–30 April)
were conducted, mainly among persons with moderate to severe COVID-19-compatible symptoms [3,11]. As the rate of testing was rather low, there were concerns regarding both the actual number of cases recorded in Greece, and the potential overestimation of the CFR of the disease [12].

Our study demonstrates low seroprevalence of SARS-CoV-2 in Greece (0.02% for March and 0.25% for April) during the first 2 months of the COVID-19 pandemic. The low seroprevalence in the Greek population may further support the hypothesis that the early implementation of public health measures in Greece resulted in the low incidence and mortality. Nevertheless, the 10-fold higher percentage in April demonstrates that community circulation of the virus had increased during that period.

A second finding of note was the higher seroprevalence in females (0.78% vs 0.22% in males). This finding contradicts reports from the NPHO in which 56% of cases until 30 April 2020 were male [3]. This difference could be attributed to convenient and non-random sampling methodology. However, at the beginning of the pandemic, only moderately or severely affected individuals were tested for SARS-CoV-2 infection in accordance with the national testing strategy. Male patients are more vulnerable to experiencing complications (73.6% of deaths and 73.7% of intensive care unit hospitalisations in Greece were males according to NPHO [3]) and as such were more likely to be tested for SARS-CoV-2. Seroprevalence is a measure of exposure and does not necessarily correlate with the severity of symptoms experienced. It should be noted that no difference was found in seroprevalence between females and males in other serosurveys conducted in Europe [13,14]. However, since we continue the serosurvey (samples for May and June have been collected and are being analysed), we have the opportunity over the next few months to further explore if this finding is consistent.

We noted a higher seroprevalence of COVID-19 in individuals 70 years and older (1.17%), suggesting that this age group was most exposed. In accordance with the characteristic age distribution for COVID-19 cases [15], we observed higher seroprevalence with increasing age. Moreover, higher seroprevalence (0.85%) was also found in large urban areas when compared with the rest of the country (0.01%), which could be explained by larger populations, crowded conditions as well as by earlier importation of COVID-19 cases from abroad. The above findings are in concordance with a recently published Spanish seroprevalence study [13].

Furthermore, the finding that for every laboratory-confirmed COVID-19 case there were ca additional 10

Table 1

| March     | Positive/sample size | S1: Crude prevalence | S2: Age, sex and population-adjusted prevalence | S3: S2 + adjustment for sensitivity and specificity | S4: S3 + NPHO dataa |
|-----------|----------------------|----------------------|-------------------------------------------------|---------------------------------------------------|----------------------|
|           | n/N                  | Prevalence (%) 95% CI| Prevalence (%) 95% CI                           | Prevalence (%) 95% CI                              | Prevalence (%) 95% CI|
| Total     | 5/2,075              | 0.24 0.03–0.45       | 0.27 0.05–0.49                                  | 0 0–0.23                                           | 0.02 0–0.25          |
| Age group (years) |                     |                      |                                                 |                                                   |                      |
| 0–29      | 0/490                | 0                    | 0                                                | 0.01 0–0.09                                        |
| 30–49     | 0/695                | 0                    | 0                                                | 0.01 0–0.10                                        |
| 50–69     | 3/533                | 0.56 0–1.20          | 0.75 0.02–1.48                                  | 0.54 0–1.41                                        | 0.56 0–1.43          |
| ≥ 70      | 2/357                | 0.56 0–1.33          | 0.55 0–1.31                                     | 0.29 0–1.21                                        | 0.30 0–1.22          |
| Sex       |                      |                      |                                                 |                                                   |                      |
| Male      | 1/928                | 0.11 0–0.32          | 0.15 0–0.39                                     | 0 0–0.11                                           | 0.01 0–0.12          |
| Female    | 4/1,147              | 0.35 0.01–0.69       | 0.40 0–0.76                                     | 0.12 0–0.55                                        | 0.14 0–0.32          |
| 'N-1' chi-squared test |                     |                      |                                                 |                                                   |                      |
| Difference between sex | Difference = 0.24%  | p = 0.269            | Difference = 0.25% p = 0.291                    | Difference = 0.12% p = 0.291                        | Difference = 0.13% p = 0.303 |
| Large urban areas | 4/1,072              | 0.37 0.01–0.74       | 0.35 0–0.71                                     | 0 0–0.37                                           | 0.02 0–0.36          |
| Rest of country | 1/1,003              | 0.10 0–0.3            | 0.13 0–0.35                                     | 0 0–0.05                                           | 0.01 0–0.06          |
| 'N-1' chi-squared test | Difference = 0.27%  | p = 0.209            | Difference = 0.22% p = 0.310                    | NA                                                | Difference = 0.01% p = 0.853 |
| Difference between large urban areas and rest of country |                     |                      |                                                 |                                                   |                      |
| CFR (%)   | 95% CI               |                      |                                                 |                                                   |                      |
| 3.61      | 2.63–4.59            | 0.22 0.12–1.77       | 0.20 0.11–1.14                                  | NA                                                | 2.66 0.64–NA         |

CFR: case fatality rate; CI: confidence interval; IFR: infection fatality rate; NA: not applicable; NPHO: National Public Health Organisation.

a NPHO data include all confirmed PCR-positive individuals.
cases, is in accordance with a recent serosurvey conducted in Switzerland [14]. This indicates the necessity of increasing testing capacity in Greece, which could potentially allow diagnosing mild or asymptomatic cases [16]. The same ratio of ca 10 was identified when we compared the estimated CFR (6.06%) with the IFR (0.59%) in April 2020. It should be noted that both CFR and IFR are estimated within a specific timeframe and the delay of death could not be accounted for in the current estimation.

The leftover sampling methodology could be considered a limitation of our study; mainly the non-random convenient sampling may affect the representativeness of the collected samples. Moreover, certain areas were not covered by the sampling framework although in total, the samples were collected from areas representing almost 90% of the Greek population. Owing to the general lockdown that was implemented, the number of routine laboratory tests was reduced and it was challenging to collect the estimated number of samples. However, this methodology has the advantage of easy sample collection and the option of repeating collection on a monthly basis, which allows following up the epidemic and drawing conclusions about public health strategies.

**Conclusion**

Our study demonstrates a low seroprevalence for COVID-19 in Greece in accordance with relatively low incidence, compared with other European Union countries. Although these findings could be attributed to the early implementation of public health measures, further research is needed to elucidate this issue. The low seroprevalence render the Greek population particularly vulnerable to a possible second COVID-19 wave and should be taken into consideration when drafting the future plan of action.

**Acknowledgements**

The authors would like thank the laboratories that participated in the study. Moreover, the authors highly appreciate the continuous support for this project offered by the General Secretary of Public Health of the Ministry of Health, Professor Panagiotis Prezerakos. Finally, the authors would like to thank the National Public Health Organization for providing surveillance data on COVID-19.

---

**Table 2**

Anti-SARS-CoV-2 IgG antibody seroprevalence, Greece, April 2020 (n = 4,511)

| April          | Positive/ sample size | S1: Crude prevalence | S2: Age, sex and population-adjusted prevalence | S3: S2 + adjustment for sensitivity and specificity | S4: S3 + NPHO data* |
|----------------|-----------------------|-----------------------|-------------------------------------------------|-------------------------------------------------|---------------------|
|                | n/N                   | Prevalence (%) 95% CI | Prevalence (%) 95% CI | Prevalence (%) 95% CI | Prevalence (%) 95% CI | Prevalence (%) 95% CI |
| Total          | 19/4,511              | 0.42 0.23–0.61        | 0.49 0.29–0.70       | 0.23 0.04–0.48       | 0.25 0.02–0.50       |
| Age group (years) |                       |                       |                    |                    |                    |                    |
| 0–29          | 4/974                 | 0.41 0.01–0.81        | 0.23 0.0–0.54       | 0 0–0.28           | 0.02 0.02–0.29      |
| 30–49         | 2/1371                | 0.15 0–0.35           | 0.09 0–0.25        | 0 0–0.01           | 0.03 0.02–0.04      |
| 50–69         | 5/1229                | 0.41 0.05–0.76        | 0.86 0.34–1.38     | 0.67 0.05–1.29     | 0.70 0.09–1.32      |
| 70+           | 8/937                 | 0.85 0.26–1.44        | 1.26 0.55–1.98    | 1.15 0.30–2.00     | 1.17 0.32–2.02      |
| Sex           |                       |                       |                    |                    |                    |                    |
| Male          | 6/2,073               | 0.29 0.06–0.53       | 0.46 0.17–0.76     | 0.19 0–0.54        | 0.22 0.03–0.57      |
| Female        | 13/2,474              | 0.53 0.26–0.81       | 0.94 0.56–1.32    | 0.76 0.31–1.21     | 0.78 0.33–1.23      |
| 'N-1' chi-squared test |               |                       |                    |                    |                    |                    |
| Difference between sex |               |                       |                    |                    |                    |                    |
| Male          |                       | 0.29 0.06–0.53       | 0.46 0.17–0.76     | 0.19 0–0.54        | 0.22 0.03–0.57      |
| Female        |                       | 0.53 0.26–0.81       | 0.94 0.56–1.32    | 0.76 0.31–1.21     | 0.78 0.33–1.23      |
| Large urban areas |                 | 0.90 0.32–1.49       | 0.99 0.38–1.61    | 0.83 0.09–1.56     | 0.85 0.11–1.58      |
| Rest of country |                  | 0.28 0.11–0.46       | 0.27 0.10–0.45    | 0 0–0.18           | 0.01 0–0.19         |
| 'N-1' chi-squared test |               |                       |                    |                    |                    |                    |
| Difference between large urban areas and rest of country |               |                       |                    |                    |                    |                    |
| Male          |                       | 0.62 0.23–0.99       | 0.72 0.38–1.26    | 0.83 0.09–1.56     | 0.85 0.11–1.58      |
| Female        |                       | 0.94 0.56–1.32       | 0.76 0.31–1.21    | 0.78 0.33–1.23     | 0.78 0.33–1.23      |

| CFR (%) | 95% CI | IFR according to: |
|---------|--------|------------------|
|         |        | S1 | S2 | S3 | S4 |
| 6.06    | 0.09–7.03 | 0.33 | 0.22–0.59 | 0.28 | 0.20–0.47 | 0.59 | 0.29–NA | 0.54 | 0.27–6.85 |

CFR: case fatality rate; CI: confidence interval; IFR: infection fatality rate; NA: not applicable; NPHO: National Public Health Organisation.

* NPHO data include all confirmed PCR-positive individuals.

* A 12-year-old girl was detected positive for SARS-COV-2 IgG antibodies among 182 children aged 0–14; thus, the S4 is estimated to be 0.001% (95% CI: 0–0.09%) for the age group 0–14 years.
Funding: The study was funded by the Greek Ministry of Health.

Conflict of interest
None declared.

Authors’ contributions
ZB: conceptualised the study, designed and conducted the serum samples collection and drafted the first draft of the paper, AV: organised the serum bank in the laboratory, supervised the laboratory testing and provided critical comments in finalising the paper, KD: was responsible for the left over sampling methodology, statistical analysis and drafting the paper, MK: Supervised the laboratory testing, the quality control and provided critical comments on the draft paper, SS: coordinated the laboratory network, supported the statistical analysis and participated in preparing the first draft of the paper, DN: conducted the lab tests and provided comments on the final draft, VM: participated in planning and designing the study as well as sample collection and provided comments on the final draft, MK: participated in the laboratory network providing left over samples and provided critical comments on the final draft, ES: participated in the laboratory network providing left over samples and provided critical comments on the final draft, GG: participated in the laboratory network providing left over samples and provided critical comments on the final draft, EN: Provided critical comments on the study protocol, supported the development of the laboratory network, provided left over samples and reviewed the final draft, AE: participated in the laboratory network providing left over samples and provided critical comments on the final draft, AV: Provided critical comments on the study protocol, supported the development of the laboratory network, provided left over samples and reviewed the final draft, EP: Supervised the laboratory testing, the quality control and provided critical comments on the draft paper, VP: Supported the development of the laboratory network, provided left over samples and reviewed the final draft, CH: conceptualised the study, designed and conducted the laboratory network development, supervised the collection of left over samples, supervised the statistical analysis and participated in preparing the first draft.

References
1. Greek Ministry of Education and Religious Affairs. 10-03-20 Προσωρινή απαγόρευση της εκπαιδευτικής λειτουργίας όλων των εκπαιδευτικών δομών [Temporary ban on the operation of all educational structures]. Athens: Greek Ministry of Education and Religious Affairs; 10 Mar 2020. Greek. Available from: https://www.minedu.gov.gr/news/44308-10-03-20-prosorini-apagorfsi-tis-ekpaideftikis-leiourgias-olon-ton-ekpaideftikon-domon
2. European Union Agency for Fundamental Rights (FRA). Coronavirus COVID-19 outbreak in the EU Fundamental Rights Implications. Vienna: FRA; 23 Mar 2020. Available from: https://fra.europa.eu/sites/default/files/fra_downloads/greece-report-covid-19-april-2020_en.pdf
3. National Public Health Organization (NPHO), Ημερίδα έκθεση επιδημιολογικών επιπτώσεων ημιολογίων από το νέο κορωνοϊό (COVID-19) Διάδοχοι Ενώμενο Ελλάδας 30 Απριλίου 2020 [Daily report of epidemiological surveillance of new coronavirus disease (COVID-19). Data until 30 April 2020]. Marousi: NPHO; 2020.

Greek. Available from: https://eody.gov.gr/wp-content/uploads/2020/04/covid-gr-daily-report-20200430.pdf
4. European Centre for Disease Prevention and Control (ECDC). COVID-19 situation update for the EU/EEA and the UK, as of 11 July 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea
5. Nardone A, Miller E, ESEN2 Group. Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2). Euro Surveill. 2004;9(4):57. https://doi.org/10.2807/e sm.09.04.00456-en PMID: 1519256
6. Naing NN. Easy way to learn standardization : direct and indirect methods. Malays J Med Sci. 2000;7(10-15). PMID: 22842409
7. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfo R, et al. COVID-19 antibody seroprevalence in Santa Clara County, California, medRxiv 2020.04.14.20062463. https://doi.org/10.1101/2020.04.14.20062463
8. MacMahon B, Trichopoulos D. Epidemiology: principles and methods: Boston: Little, Brown and Company; 1996.
9. Diggie PJ. Estimating prevalence using an imperfect test. Epidemiol Res Int. 2011;2011:608719. https://doi.org/10.1555/2011/608719
10. Campbell I, Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med. 2007;26(19):3661-75. https://doi.org/10.1002/sim.2832 PMID: 17315184
11. Our World in Data. Daily COVID-19 tests per thousand people —Greece Oxford: University of Oxford; 2020. Available from: https://ourworldindata.org/coronavirus-testing#greece
12. World Health Organization (WHO). Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, 17 March 2020. Geneva: WHO; 2020. Available from: https://apps.who.int/iris/handle/10665/331656
13. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020.
15. Strighlini S, Wisniak A, Plumatti G, Azman AS, Lauer SA, Bayssons H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;S0140-6736(20)31304-0. Ahead of print.
16. World Health Organization (WHO). Transmission of SARS-CoV-2: implications for infection prevention precautions. Geneva: WHO; 9 Jul 2020. Available from: https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions

License, supplementary material and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2020.